Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma

Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma Hindawi Case Reports in Oncological Medicine Volume 2019, Article ID 7928752, 4 pages https://doi.org/10.1155/2019/7928752 Case Report Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma 1 2 1 1 3 Osama Diab, Dan Mcentire, Thamer Kassim , Ali Nayfeh , Abdel Rahman Dajani, 4 1 5 1 Mitchell Kerfeld, Jonathon Campbell, Adbullah Alsuwaidan, Mahmoud Abu Hazeem , and Maryam Gbadamosi-Akindele Department of Medicine, Creighton University, Omaha, NE, USA Department of Medicine, University of Utah, Salt Lake City, UT, USA Department of Medicine, Norwalk Hospital, Norwalk, CT, USA Department of Pathology, Creighton University, Omaha, NE, USA Department of Anesthesia, Mayo Clinic, Rochester, MN, USA Correspondence should be addressed to Maryam Gbadamosi-Akindele; maryamgbadamosi@creighton.edu Received 26 June 2018; Accepted 9 December 2018; Published 8 January 2019 Academic Editor: Constantine Gennatas Copyright © 2019 Osama Diab et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Docetaxel is a commonly used chemotherapeutic agent in a variety of cancer treatment regimens. We present a case of apparent docetaxel-induced Stevens-Johnson syndrome (SJS) in a patient recently treated for metastatic prostate cancer. This medication is not classically associated with the development of SJS but in our case, along with a number of other case reports, and a single phase II clinical trial, an association was recognized. We encourage clinicians who employ the use of this medication to be aware of this relationship. 1. Introduction especially painful in the hands and feet. He also reported red eyes and difficulty eating for the past week. Stevens-Johnson syndrome (SJS) is a severe and potentially Vital signs upon presentation were as follows: tempera- life-threatening skin condition that is associated with a num- ture 36.4 C, pulse 83/min, respiratory rate 12/min, and blood ber of medications and a few infectious agents. This condi- pressure 121/60 mmHg. Physical examination of the patient tion, characterized by the separation of the epidermis from revealed a severe rash covering less than thirty percent of the underlying dermis, typically presents with a severe and the body, oral ulcers, and conjunctival redness (Figure 1). painful rash that includes the conjunctiva and oral mucosa Laboratory data at the time of admission is notable for leuko- and is considered a dermatological emergency. Here, we cytosis, electrolyte imbalances, and hepatic dysfunction present a case of apparent docetaxel-induced SJS, an associa- (Table 1). tion that has not been officially recognized. The patient’s current cancer treatment regimen included active hormonal therapy with leuprolide and active chemo- therapy with docetaxel. He had received two cycles of doce- 2. Case Report taxel therapy (generic form: 75 mg/m ), with the last dose A 63-year-old male with a past medical history of hyperten- of docetaxel received two weeks prior to presentation. He sion, hyperlipidemia, and metastatic prostate adenocarci- was not on other medications at the time of admission. noma to retroperitoneal lymph nodes, lung, and bone Treatment of the patient included intravenous fluid presented to the emergency room with a one-week history replacement, prednisone, piperacillin/tazobactam, ondanse- of a rash. The rash affected the hands, feet, back, and chest. tron, and morphine. Wound and eye care were provided. It developed into blisters that later ruptured. The rash was Dermatology was consulted. 2 Case Reports in Oncological Medicine (a) (b) (a) (b) (c) (d) (c) (d) Figure 2: Biopsy images and pathology report. Microscopic examination of the skin (hematoxylin and eosin stain) was performed. The punch biopsies from the edges of both lesions (left forearm and left medial foot) show similar morphologic features. There is a predominantly normal intact stratum corneum overlying the epidermis. Within the dermis, there is interface dermatitis with a superficial perivascular infiltrate of lymphocytes with occasional neutrophils (a). Additionally, basal vacuolization with dyskeratotic keratinocytes scattered throughout all levels of (e) (f) the epidermis is seen. Mild interstitial and periadnexal lymphocytic inflammation are noted (b) as well as a focal area of neutrophils Figure 1: Patient images. Physical examination showed conjunctival, present in the keratin plug of a hair follicle (c). There is a focal area mucosal, and skin involvement. Stevens-Johnson syndrome affects of incipient epidermal detachment present (d). No fungal elements less than 30% of the body surface area and commonly affects or eosinophilic infiltration are noted in the specimens. The mucous membranes. The photographs presented in Figure 2 were histologic features are consistent with toxic epidermal necrolysis/ obtained with patient permission and depict the lesions throughout Stevens-Johnson syndrome. his body. (a) Involvement of the conjunctiva of the right eye. (b) Mucosal ulcers of the oropharynx. (c–f) Other areas of skin involvement that totaled to less than 30% of total body surface. Because our searches for an established association Table 1: Laboratory data at the time of admission. Notable between SJS and docetaxel were in vain, we elected to obtain abnormalities include leukocytosis, electrolyte imbalances, and a punch biopsy of the lesions to establish pathological evi- hepatic dysfunction. dence of our diagnosis. The punch biopsies were obtained from the edges of lesions on the left forearm and left medial Laboratory test Value Reference range foot. Light microscopy of the hematoxylin and eosin- White blood cell count (k/μl) 28.3 4.0-12.0 stained specimens were confirmatory for SJS (Figure 2). Hemoglobin (gm/dl) 12.0 13.5-17.5 The patient clinically improved with supportive therapy Platelet (k/μl) 176 140-440 and was discharged home. He was scheduled a follow-up Sodium (mmol/l) 130 135-145 with his oncologist to discuss other treatment options. Potassium (mmol/l) 3.3 3.7-5.1 Chloride (mmol/l) 97 96-110 3. Discussion Carbon dioxide (mmol/l) 26 22.0-32.0 Blood urea nitrogen (mg/dl) 15 6-24 Docetaxel is an antitubulin agent that inhibits mitosis by sta- Creatinine (mg/dl) 0.8 0.60-1.30 bilizing microtubule assembly. It is a widely used chemother- Glucose (mg/dl) 112 70-100 apeutic agent in the treatment of breast, lung, prostate, and Calcium (mg/dl) 7.9 8.5-10.5 other cancers [1]. The classically known side effects of doce- Protein (gm/dl) 5.8 6.0-8.4 taxel therapy include alopecia, pancytopenia, drug-induced Albumin (gm/dl) 2.6 3.5-5.0 liver injury, nausea, vomiting, and diarrhea. There have been an increasing number of generic docetaxel toxicities in com- Bilirubin (mg/dl) 3.6 0.0-1.5 parison to the original drug formulation. Impurities, excipi- Alkaline phosphatase (u/l) 323 33-138 ents, and the amount of active agent itself can all have an Aspartate aminotransferase (u/l) 156 10-40 impact on the efficacy of the drug and impact its narrow ther- Alanine aminotransferase (u/l) 48 12-78 apeutic index resulting in increased side effects [2]. Case Reports in Oncological Medicine 3 Table 2: Reported cases of docetaxel-induced SJS. Type of Author Year Description of case/study Outcome article 76-year-old female with metastatic breast Resolution of symptoms after 3 weeks Moisidis and Möbus [1] 2005 Case report cancer with docetaxel-induced erythema following treatment with high-dose steroids multiforme 60-year-old patient with non-Hodgkin’s lymphoma and received salvage therapy with Received treatment with supportive Dourakis et al. [5] 2002 Case report docetaxel and prednisone developed SJS measures and survived within 5 days of treatment 46-year-old female with metastatic breast Arshad et al. [6] 2014 Case report cancer developed SJS two weeks following She was supportively managed. treatment with three cycles of docetaxel. She received treatment with topical 56-year-old female treated for metastatic clobetasol and triamcinolone and other Sawada et al. [7] 2009 Case report breast cancer with first cycle of docetaxel supportive measures. The patient survived developed SJS. with resolution of symptoms. 67-year-old male with prostate cancer Patient received systemic steroids and received docetaxel as a part of a randomized Ohlmann et al. [8] 2007 Case report antibiotics for treatment and succumbed as a phase III trial developed SJS after five cycles result of SJS secondary to docetaxel. of treatment. 27 patients received weekly docetaxel and Clinical trial, zoledronic acid and estramustine between 1 patient died of docetaxel toxicity in the Kattan et al. [9] 2008 open-labelled 2002 and 2014 for hormone refractory form of SJS, 2 weeks after the second cycle. phase II prostate cancer. A number of popular clinical pharmacology resources do Moisidis and Möbus [1] encountered skin lesions consistent not include Stevens-Johnson syndrome (SJS) as a known with erythema multiforme and SJS. Ohlmann et al. [8] complication of docetaxel chemotherapy. However, the cur- reported the course of a patient receiving docetaxel who rent case and the cases written by a handful of other clini- developed SJS and acute hepatic failure and died 6 weeks cians may provide clinical evidence that docetaxel therapy later. Kattan et al. [9] carried out a phase II trial to establish is associated with the development of this potentially life- the safety of the combination of docetaxel, zoledronic acid, threatening dermatologic condition. and estramustine in patients with metastatic prostate carci- Stevens-Johnson syndrome is one of the life-threatening noma. Of the 27 patients included in the trial, one patient dermatologic diseases, which is characterized by skin and died of SJS with liver failure. mucosal involvement and systemic symptoms. Most often, An interesting point of discussion relative to this case is, SJS is secondary to medication use but it also could be related first, the finding of elevated liver function tests. Our patient to an infection [3]. The treatment of this condition remains did not have a history of hepatic disease. However, docetaxel controversial but all reach agreement that supportive man- is known to be associated with hepatotoxicity [10]. This asso- agement is first line and the use of steroids, IVIG, tumor ciation may be relevant because a number of case reports necrosis factor, or even cyclosporine lacks powered data. summarized by Devarbhavi et al. [11] reported that patients with drug-induced liver dysfunction and SJS have poorer The mortality rate of SJS in severe cases could exceed 90 percent [4]. outcomes. These findings were especially prevalent in The existing reported cases of SJS-like skin reactions in patients taking antiepileptics, antiretrovirals, and sulfon- association with docetaxel are few (Table 2). Dourakis et al. amides. Although it is unknown whether liver dysfunction [5] described a case of a 60-year-old woman that received predisposes patients to SJS, there appears to be an association that should be noted by physicians. docetaxel as salvage chemotherapy for non-Hodgkin’s lym- phoma who developed toxic epidermal necrolysis. Similarly, Arshad et al. [6] shared a case of a 40-year-old woman receiving docetaxel for invasive ductal breast carcinoma 4. Conclusion who developed toxic epidermal necrolysis. Despite aggres- sive supportive measures, the patient died. Sawada et al. We recognize that a number of other authors have encoun- [7] reported the development of SJS in a patient with meta- tered apparent docetaxel-induced SJS and our report adds static breast cancer after a single dose. This case also pro- to the growing body of knowledge of this detrimental rela- vided pathological evidence of SJS and ruled out conditions tionship. We encourage clinicians that employ the use of this such as pemphigus vulgaris. Following the seventh dose of medication to be cognizant of the risk of SJS and to treat this docetaxel in another patient with metastatic breast cancer, condition early and aggressively. 4 Case Reports in Oncological Medicine Disclosure The details of this manuscript were presented as a poster presentation at the 2016 Association of Veteran Affairs Hematology Oncology (AVAHO) annual meeting on 09/24/ 2016 at the Renaissance Hotel in Dallas, Texas. Conflicts of Interest The authors declare that they have no conflicts of interest. References [1] C. Moisidis and V. Möbus, “Erythema multiforme major following docetaxel,” Archives of Gynecology and Obstetrics, vol. 271, no. 3, pp. 268–270, 2005. [2] C. Elm’hadi, R. Tanz, M. R. Khmamouche et al., “Toxicities of docetaxel: original drug versus generics—a comparative study about 81 cases,” SpringerPlus, vol. 5, no. 1, p. 732, 2016. [3] N. Frey, J. Jossi, M. Bodmer et al., “The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK,” Journal of Investigative Dermatology, vol. 137, no. 6, pp. 1240–1247, 2017. [4] J. A. Schneider and P. R. Cohen, “Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a com- prehensive summary of therapeutic interventions emphasizing supportive measures,” Advances in Therapy, vol. 34, no. 6, pp. 1235–1244, 2017. [5] S. P. Dourakis, V. A. Sevastianos, A. Alexopoulou, M. Deutsch, and N. Stavrianeas, “Treatment side effects: case 2. toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy,” Journal of Clinical Oncology, vol. 20, no. 13, pp. 3030–3032, 2002. [6] F. Arshad, T. Bhat, and A. Lone, “Docetaxel induced Lyell’s syndrome: a rare life threatening cause of dermatitis medica- mentosas,” Journal of Cancer Research and Therapeutics, vol. 10, no. 3, pp. 742–744, 2014. [7] Y. Sawada, K. Sugita, R. Kabashima, M. Nakamura, and Y. Tokura, “Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratino- cytes,” Journal of the European Academy of Dermatology and Venereology, vol. 23, no. 11, pp. 1333–1335, 2009. [8] C. H. Ohlmann, S. Kohlmorgen, D. Sahi, U. Engelmann, and A. Heidenreich, “Letaler ausgang einer chemotherapie mit docetaxel,” Der Urologe, vol. 46, no. 10, pp. 1425–1427, 2007. [9] J. G. Kattan, F. S. Farhat, G. Y. Chahine et al., “Weekly doce- taxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC),” Investigational New Drugs, vol. 26, no. 1, pp. 75–79, 2008. [10] Z. Wang, X. Liang, J. Yu et al., “Non-genetic risk factors and predicting efficacy for docetaxel-drug-induced liver injury among metastatic breast cancer patients,” Journal of Gastroen- terology and Hepatology, vol. 27, no. 8, pp. 1348–1352, 2012. [11] H. Devarbhavi, S. Raj, V. H. Aradya et al., “Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epi- dermal necrolysis: patient characteristics, causes, and outcome in 36 cases,” Hepatology, vol. 63, no. 3, pp. 993–999, 2016. MEDIATORS of INFLAMMATION The Scientific Gastroenterology Journal of World Journal Research and Practice Diabetes Research Disease Markers Hindawi Hindawi Publishing Corporation Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 http://www www.hindawi.com .hindawi.com V Volume 2018 olume 2013 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 International Journal of Journal of Immunology Research Endocrinology Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 Submit your manuscripts at www.hindawi.com BioMed PPAR Research Research International Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 Journal of Obesity Evidence-Based Journal of Journal of Stem Cells Complementary and Ophthalmology International Alternative Medicine Oncology Hindawi Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2013 Parkinson’s Disease Computational and Behavioural Mathematical Methods AIDS Oxidative Medicine and in Medicine Neurology Research and Treatment Cellular Longevity Hindawi Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Case Reports in Oncological Medicine Hindawi Publishing Corporation

Loading next page...
 
/lp/hindawi-publishing-corporation/docetaxel-induced-stevens-johnson-syndrome-in-a-patient-with-rq4UAbn8XF
Publisher
Hindawi Publishing Corporation
Copyright
Copyright © 2019 Osama Diab et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN
2090-6706
eISSN
2090-6714
DOI
10.1155/2019/7928752
Publisher site
See Article on Publisher Site

Abstract

Hindawi Case Reports in Oncological Medicine Volume 2019, Article ID 7928752, 4 pages https://doi.org/10.1155/2019/7928752 Case Report Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma 1 2 1 1 3 Osama Diab, Dan Mcentire, Thamer Kassim , Ali Nayfeh , Abdel Rahman Dajani, 4 1 5 1 Mitchell Kerfeld, Jonathon Campbell, Adbullah Alsuwaidan, Mahmoud Abu Hazeem , and Maryam Gbadamosi-Akindele Department of Medicine, Creighton University, Omaha, NE, USA Department of Medicine, University of Utah, Salt Lake City, UT, USA Department of Medicine, Norwalk Hospital, Norwalk, CT, USA Department of Pathology, Creighton University, Omaha, NE, USA Department of Anesthesia, Mayo Clinic, Rochester, MN, USA Correspondence should be addressed to Maryam Gbadamosi-Akindele; maryamgbadamosi@creighton.edu Received 26 June 2018; Accepted 9 December 2018; Published 8 January 2019 Academic Editor: Constantine Gennatas Copyright © 2019 Osama Diab et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Docetaxel is a commonly used chemotherapeutic agent in a variety of cancer treatment regimens. We present a case of apparent docetaxel-induced Stevens-Johnson syndrome (SJS) in a patient recently treated for metastatic prostate cancer. This medication is not classically associated with the development of SJS but in our case, along with a number of other case reports, and a single phase II clinical trial, an association was recognized. We encourage clinicians who employ the use of this medication to be aware of this relationship. 1. Introduction especially painful in the hands and feet. He also reported red eyes and difficulty eating for the past week. Stevens-Johnson syndrome (SJS) is a severe and potentially Vital signs upon presentation were as follows: tempera- life-threatening skin condition that is associated with a num- ture 36.4 C, pulse 83/min, respiratory rate 12/min, and blood ber of medications and a few infectious agents. This condi- pressure 121/60 mmHg. Physical examination of the patient tion, characterized by the separation of the epidermis from revealed a severe rash covering less than thirty percent of the underlying dermis, typically presents with a severe and the body, oral ulcers, and conjunctival redness (Figure 1). painful rash that includes the conjunctiva and oral mucosa Laboratory data at the time of admission is notable for leuko- and is considered a dermatological emergency. Here, we cytosis, electrolyte imbalances, and hepatic dysfunction present a case of apparent docetaxel-induced SJS, an associa- (Table 1). tion that has not been officially recognized. The patient’s current cancer treatment regimen included active hormonal therapy with leuprolide and active chemo- therapy with docetaxel. He had received two cycles of doce- 2. Case Report taxel therapy (generic form: 75 mg/m ), with the last dose A 63-year-old male with a past medical history of hyperten- of docetaxel received two weeks prior to presentation. He sion, hyperlipidemia, and metastatic prostate adenocarci- was not on other medications at the time of admission. noma to retroperitoneal lymph nodes, lung, and bone Treatment of the patient included intravenous fluid presented to the emergency room with a one-week history replacement, prednisone, piperacillin/tazobactam, ondanse- of a rash. The rash affected the hands, feet, back, and chest. tron, and morphine. Wound and eye care were provided. It developed into blisters that later ruptured. The rash was Dermatology was consulted. 2 Case Reports in Oncological Medicine (a) (b) (a) (b) (c) (d) (c) (d) Figure 2: Biopsy images and pathology report. Microscopic examination of the skin (hematoxylin and eosin stain) was performed. The punch biopsies from the edges of both lesions (left forearm and left medial foot) show similar morphologic features. There is a predominantly normal intact stratum corneum overlying the epidermis. Within the dermis, there is interface dermatitis with a superficial perivascular infiltrate of lymphocytes with occasional neutrophils (a). Additionally, basal vacuolization with dyskeratotic keratinocytes scattered throughout all levels of (e) (f) the epidermis is seen. Mild interstitial and periadnexal lymphocytic inflammation are noted (b) as well as a focal area of neutrophils Figure 1: Patient images. Physical examination showed conjunctival, present in the keratin plug of a hair follicle (c). There is a focal area mucosal, and skin involvement. Stevens-Johnson syndrome affects of incipient epidermal detachment present (d). No fungal elements less than 30% of the body surface area and commonly affects or eosinophilic infiltration are noted in the specimens. The mucous membranes. The photographs presented in Figure 2 were histologic features are consistent with toxic epidermal necrolysis/ obtained with patient permission and depict the lesions throughout Stevens-Johnson syndrome. his body. (a) Involvement of the conjunctiva of the right eye. (b) Mucosal ulcers of the oropharynx. (c–f) Other areas of skin involvement that totaled to less than 30% of total body surface. Because our searches for an established association Table 1: Laboratory data at the time of admission. Notable between SJS and docetaxel were in vain, we elected to obtain abnormalities include leukocytosis, electrolyte imbalances, and a punch biopsy of the lesions to establish pathological evi- hepatic dysfunction. dence of our diagnosis. The punch biopsies were obtained from the edges of lesions on the left forearm and left medial Laboratory test Value Reference range foot. Light microscopy of the hematoxylin and eosin- White blood cell count (k/μl) 28.3 4.0-12.0 stained specimens were confirmatory for SJS (Figure 2). Hemoglobin (gm/dl) 12.0 13.5-17.5 The patient clinically improved with supportive therapy Platelet (k/μl) 176 140-440 and was discharged home. He was scheduled a follow-up Sodium (mmol/l) 130 135-145 with his oncologist to discuss other treatment options. Potassium (mmol/l) 3.3 3.7-5.1 Chloride (mmol/l) 97 96-110 3. Discussion Carbon dioxide (mmol/l) 26 22.0-32.0 Blood urea nitrogen (mg/dl) 15 6-24 Docetaxel is an antitubulin agent that inhibits mitosis by sta- Creatinine (mg/dl) 0.8 0.60-1.30 bilizing microtubule assembly. It is a widely used chemother- Glucose (mg/dl) 112 70-100 apeutic agent in the treatment of breast, lung, prostate, and Calcium (mg/dl) 7.9 8.5-10.5 other cancers [1]. The classically known side effects of doce- Protein (gm/dl) 5.8 6.0-8.4 taxel therapy include alopecia, pancytopenia, drug-induced Albumin (gm/dl) 2.6 3.5-5.0 liver injury, nausea, vomiting, and diarrhea. There have been an increasing number of generic docetaxel toxicities in com- Bilirubin (mg/dl) 3.6 0.0-1.5 parison to the original drug formulation. Impurities, excipi- Alkaline phosphatase (u/l) 323 33-138 ents, and the amount of active agent itself can all have an Aspartate aminotransferase (u/l) 156 10-40 impact on the efficacy of the drug and impact its narrow ther- Alanine aminotransferase (u/l) 48 12-78 apeutic index resulting in increased side effects [2]. Case Reports in Oncological Medicine 3 Table 2: Reported cases of docetaxel-induced SJS. Type of Author Year Description of case/study Outcome article 76-year-old female with metastatic breast Resolution of symptoms after 3 weeks Moisidis and Möbus [1] 2005 Case report cancer with docetaxel-induced erythema following treatment with high-dose steroids multiforme 60-year-old patient with non-Hodgkin’s lymphoma and received salvage therapy with Received treatment with supportive Dourakis et al. [5] 2002 Case report docetaxel and prednisone developed SJS measures and survived within 5 days of treatment 46-year-old female with metastatic breast Arshad et al. [6] 2014 Case report cancer developed SJS two weeks following She was supportively managed. treatment with three cycles of docetaxel. She received treatment with topical 56-year-old female treated for metastatic clobetasol and triamcinolone and other Sawada et al. [7] 2009 Case report breast cancer with first cycle of docetaxel supportive measures. The patient survived developed SJS. with resolution of symptoms. 67-year-old male with prostate cancer Patient received systemic steroids and received docetaxel as a part of a randomized Ohlmann et al. [8] 2007 Case report antibiotics for treatment and succumbed as a phase III trial developed SJS after five cycles result of SJS secondary to docetaxel. of treatment. 27 patients received weekly docetaxel and Clinical trial, zoledronic acid and estramustine between 1 patient died of docetaxel toxicity in the Kattan et al. [9] 2008 open-labelled 2002 and 2014 for hormone refractory form of SJS, 2 weeks after the second cycle. phase II prostate cancer. A number of popular clinical pharmacology resources do Moisidis and Möbus [1] encountered skin lesions consistent not include Stevens-Johnson syndrome (SJS) as a known with erythema multiforme and SJS. Ohlmann et al. [8] complication of docetaxel chemotherapy. However, the cur- reported the course of a patient receiving docetaxel who rent case and the cases written by a handful of other clini- developed SJS and acute hepatic failure and died 6 weeks cians may provide clinical evidence that docetaxel therapy later. Kattan et al. [9] carried out a phase II trial to establish is associated with the development of this potentially life- the safety of the combination of docetaxel, zoledronic acid, threatening dermatologic condition. and estramustine in patients with metastatic prostate carci- Stevens-Johnson syndrome is one of the life-threatening noma. Of the 27 patients included in the trial, one patient dermatologic diseases, which is characterized by skin and died of SJS with liver failure. mucosal involvement and systemic symptoms. Most often, An interesting point of discussion relative to this case is, SJS is secondary to medication use but it also could be related first, the finding of elevated liver function tests. Our patient to an infection [3]. The treatment of this condition remains did not have a history of hepatic disease. However, docetaxel controversial but all reach agreement that supportive man- is known to be associated with hepatotoxicity [10]. This asso- agement is first line and the use of steroids, IVIG, tumor ciation may be relevant because a number of case reports necrosis factor, or even cyclosporine lacks powered data. summarized by Devarbhavi et al. [11] reported that patients with drug-induced liver dysfunction and SJS have poorer The mortality rate of SJS in severe cases could exceed 90 percent [4]. outcomes. These findings were especially prevalent in The existing reported cases of SJS-like skin reactions in patients taking antiepileptics, antiretrovirals, and sulfon- association with docetaxel are few (Table 2). Dourakis et al. amides. Although it is unknown whether liver dysfunction [5] described a case of a 60-year-old woman that received predisposes patients to SJS, there appears to be an association that should be noted by physicians. docetaxel as salvage chemotherapy for non-Hodgkin’s lym- phoma who developed toxic epidermal necrolysis. Similarly, Arshad et al. [6] shared a case of a 40-year-old woman receiving docetaxel for invasive ductal breast carcinoma 4. Conclusion who developed toxic epidermal necrolysis. Despite aggres- sive supportive measures, the patient died. Sawada et al. We recognize that a number of other authors have encoun- [7] reported the development of SJS in a patient with meta- tered apparent docetaxel-induced SJS and our report adds static breast cancer after a single dose. This case also pro- to the growing body of knowledge of this detrimental rela- vided pathological evidence of SJS and ruled out conditions tionship. We encourage clinicians that employ the use of this such as pemphigus vulgaris. Following the seventh dose of medication to be cognizant of the risk of SJS and to treat this docetaxel in another patient with metastatic breast cancer, condition early and aggressively. 4 Case Reports in Oncological Medicine Disclosure The details of this manuscript were presented as a poster presentation at the 2016 Association of Veteran Affairs Hematology Oncology (AVAHO) annual meeting on 09/24/ 2016 at the Renaissance Hotel in Dallas, Texas. Conflicts of Interest The authors declare that they have no conflicts of interest. References [1] C. Moisidis and V. Möbus, “Erythema multiforme major following docetaxel,” Archives of Gynecology and Obstetrics, vol. 271, no. 3, pp. 268–270, 2005. [2] C. Elm’hadi, R. Tanz, M. R. Khmamouche et al., “Toxicities of docetaxel: original drug versus generics—a comparative study about 81 cases,” SpringerPlus, vol. 5, no. 1, p. 732, 2016. [3] N. Frey, J. Jossi, M. Bodmer et al., “The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK,” Journal of Investigative Dermatology, vol. 137, no. 6, pp. 1240–1247, 2017. [4] J. A. Schneider and P. R. Cohen, “Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a com- prehensive summary of therapeutic interventions emphasizing supportive measures,” Advances in Therapy, vol. 34, no. 6, pp. 1235–1244, 2017. [5] S. P. Dourakis, V. A. Sevastianos, A. Alexopoulou, M. Deutsch, and N. Stavrianeas, “Treatment side effects: case 2. toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy,” Journal of Clinical Oncology, vol. 20, no. 13, pp. 3030–3032, 2002. [6] F. Arshad, T. Bhat, and A. Lone, “Docetaxel induced Lyell’s syndrome: a rare life threatening cause of dermatitis medica- mentosas,” Journal of Cancer Research and Therapeutics, vol. 10, no. 3, pp. 742–744, 2014. [7] Y. Sawada, K. Sugita, R. Kabashima, M. Nakamura, and Y. Tokura, “Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratino- cytes,” Journal of the European Academy of Dermatology and Venereology, vol. 23, no. 11, pp. 1333–1335, 2009. [8] C. H. Ohlmann, S. Kohlmorgen, D. Sahi, U. Engelmann, and A. Heidenreich, “Letaler ausgang einer chemotherapie mit docetaxel,” Der Urologe, vol. 46, no. 10, pp. 1425–1427, 2007. [9] J. G. Kattan, F. S. Farhat, G. Y. Chahine et al., “Weekly doce- taxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC),” Investigational New Drugs, vol. 26, no. 1, pp. 75–79, 2008. [10] Z. Wang, X. Liang, J. Yu et al., “Non-genetic risk factors and predicting efficacy for docetaxel-drug-induced liver injury among metastatic breast cancer patients,” Journal of Gastroen- terology and Hepatology, vol. 27, no. 8, pp. 1348–1352, 2012. [11] H. Devarbhavi, S. Raj, V. H. Aradya et al., “Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epi- dermal necrolysis: patient characteristics, causes, and outcome in 36 cases,” Hepatology, vol. 63, no. 3, pp. 993–999, 2016. MEDIATORS of INFLAMMATION The Scientific Gastroenterology Journal of World Journal Research and Practice Diabetes Research Disease Markers Hindawi Hindawi Publishing Corporation Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 http://www www.hindawi.com .hindawi.com V Volume 2018 olume 2013 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 International Journal of Journal of Immunology Research Endocrinology Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 Submit your manuscripts at www.hindawi.com BioMed PPAR Research Research International Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 Journal of Obesity Evidence-Based Journal of Journal of Stem Cells Complementary and Ophthalmology International Alternative Medicine Oncology Hindawi Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2013 Parkinson’s Disease Computational and Behavioural Mathematical Methods AIDS Oxidative Medicine and in Medicine Neurology Research and Treatment Cellular Longevity Hindawi Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018

Journal

Case Reports in Oncological MedicineHindawi Publishing Corporation

Published: Jan 8, 2019

References